Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | RXRA | P19793 | 2/20 | 0.34 |
| ▸ | RXRB | P28702 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | NPC1L1 | Q9UHC9 | 3/20 | 0.34 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.34 |
| ▸ | PDE5A | O76074 | 5/20 | 0.34 |
| ▸ | RARA | P10276 | 1/20 | 0.33 |
| ▸ | RARB | P10826 | 1/20 | 0.33 |
| ▸ | RARG | P13631 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL601315 | 1.00 | ALDH1A1 (0.36) | ALDH1A1RXRARXRBMAPTNPC1L1 | |
| SCHEMBL601880 | 0.85 | RAB9A (0.39) | ALDH1A1MAPTCYP2C9 | |
| SCHEMBL13255509 | 0.85 | RAB9A (0.39) | ALDH1A1MAPTCYP2C9 | |
| SCHEMBL3669960 | 0.81 | JAK2 (0.44) | JAK2SYKMRGPRX4 | |
| SCHEMBL600832 | 0.79 | NPC1 (0.42) | ALDH1A1MAPTP2RY14PDE5ACYP2C9 | |
| SCHEMBL10188595 | 0.79 | NPC1 (0.42) | ALDH1A1MAPTP2RY14PDE5ACYP2C9 | |
| SCHEMBL602434 | 0.75 | DGAT1 (0.61) | — | |
| SCHEMBL10188561 | 0.72 | PDE5A (0.38) | ALDH1A1MAPTP2RY14PDE5ACYP2C9 | |
| SCHEMBL601842 | 0.72 | PDE5A (0.38) | ALDH1A1MAPTP2RY14PDE5ACYP2C9 | |
| SCHEMBL601843 | 0.72 | PDE5A (0.38) | ALDH1A1MAPTP2RY14PDE5ACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120040984-A1 | THIADIAZOLE AND OXADIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040984-A1 | THIADIAZOLE AND OXADIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | OXA1L, CYP11B2, CYP11B1 | ALDH1A1 126/4885RXRA 4149/4885RXRB 3892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.